ELVN vs XENE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ELVN · Enliven Therapeutics$49.43 ▲ 10.36%
XENE · Xenon Pharmaceuticals$39.17 ▲ 3.95%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ELVN +164.2%
- XENE +2.0%
Head to head
| Metric | ELVN | XENE |
|---|---|---|
| Price | $49.43 | $39.17 |
| Change today | ▲ 10.36% | ▲ 3.95% |
| Market cap | $3.64B | $3.79B |
| Return, 3 months | -16.8% | -39.0% |
| Return, year to date | +221.0% | -12.6% |
| Return, 1 year | +180.4% | +2.4% |
| P/E (TTM) | – | – |
| P/B | 4.1 | 3.1 |
| P/E percentile vs own 5y | 21st | 98th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -28.2% | -30.7% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -15.3% | -43.6% |
| Analyst target vs. price | +50.4% | +89.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 64 | 53 |
| 30-day volatility | 56.5% | 37.9% |
| Max drawdown, 1 year | -39.0% | -52.8% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- XENE is the largest of the group by market value.
- ELVN has returned the most over the past year.
- XENE has been the calmest stock over the last 30 days.